17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Repression of E-cadherin by the polycomb group protein EZH2 in cancer.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Enhancer of zeste homolog 2 (EZH2) is a critical component of the polycomb-repressive complex 2 (PRC2), which is involved in gene silencing and histone H3 lysine 27 methylation. EZH2 has a master regulatory function in controlling such processes as stem cell differentiation, cell proliferation, early embryogenesis and X chromosome inactivation. Although benign epithelial cells express very low levels of EZH2, increased levels of EZH2 have been observed in aggressive solid tumors such as those of the prostate, breast and bladder. The mechanism by which EZH2 mediates tumor aggressiveness is unclear. Here, we demonstrate that EZH2 mediates transcriptional silencing of the tumor suppressor gene E-cadherin by trimethylation of H3 lysine 27. Histone deacetylase inhibitors can prevent EZH2-mediated repression of E-cadherin and attenuate cell invasion, suggesting a possible mechanism that may be useful for the development of therapeutic treatments. Taken together, these observations provide a novel mechanism of E-cadherin regulation and establish a functional link between dysregulation of EZH2 and repression of E-cadherin during cancer progression.

          Related collections

          Author and article information

          Journal
          Oncogene
          Oncogene
          Springer Science and Business Media LLC
          1476-5594
          0950-9232
          Dec 11 2008
          : 27
          : 58
          Affiliations
          [1 ] Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109-0602, USA.
          Article
          onc2008333 NIHMS104449
          10.1038/onc.2008.333
          2690514
          18806826
          e9c612ce-af99-4e30-9083-832e6ea4e4ae
          History

          Comments

          Comment on this article